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IMMEDIATE COMMUNICATION
GWAS meta-analysis reveals novel loci and genetic correlates
for general cognitive function: a report from the COGENT
consortium
JW Trampush1,56, MLZ Yang2,56, J Yu1,3, E Knowles4, G Davies5,6, DC Liewald6, JM Starr5,7, S Djurovic8,9, I Melle9,10, K Sundet10,11,
A Christoforou9,12, I Reinvang11, P DeRosse1,3, AJ Lundervold13, VM Steen9,12, T Espeseth10,11, K Räikkönen14, E Widen15, A Palotie15,16,17,
JG Eriksson18,19,20,21, I Giegling22, B Konte22, P Roussos23,24,25, S Giakoumaki26, KE Burdick23,25, A Payton27,28, W Ollier29, M Horan30,
O Chiba-Falek31, DK Attix31,32, AC Need33, ET Cirulli34, AN Voineskos35, NC Stefanis36,37,38, D Avramopoulos39,40, A Hatzimanolis36,37,38,
DE Arking40, N Smyrnis36,37, RM Bilder41, NA Freimer41, TD Cannon42, E London41, RA Poldrack43, FW Sabb44, E Congdon41, ED Conley45,
MA Scult46, D Dickinson47, RE Straub48, G Donohoe49, D Morris50, A Corvin50, M Gill50, AR Hariri46, DR Weinberger48, N Pendleton29,30,
P Bitsios51, D Rujescu22, J Lahti14,52, S Le Hellard9,12, MC Keller53, OA Andreassen9,10,54, IJ Deary5,6, DC Glahn4, AK Malhotra1,3,55 and
T Lencz1,3,55
The complex nature of human cognition has resulted in cognitive genomics lagging behind many other fields in terms of gene
discovery using genome-wide association study (GWAS) methods. In an attempt to overcome these barriers, the current study
utilized GWAS meta-analysis to examine the association of common genetic variation (~8M single-nucleotide polymorphisms (SNP)
with minor allele frequency ⩾ 1%) to general cognitive function in a sample of 35 298 healthy individuals of European ancestry
across 24 cohorts in the Cognitive Genomics Consortium (COGENT). In addition, we utilized individual SNP lookups and polygenic
score analyses to identify genetic overlap with other relevant neurobehavioral phenotypes. Our primary GWAS meta-analysis
identified two novel SNP loci (top SNPs: rs76114856 in the CENPO gene on chromosome 2 and rs6669072 near LOC105378853 on
chromosome 1) associated with cognitive performance at the genome-wide significance level (Po5 × 10− 8). Gene-based analysis
identified an additional three Bonferroni-corrected significant loci at chromosomes 17q21.31, 17p13.1 and 1p13.3. Altogether,
common variation across the genome resulted in a conservatively estimated SNP heritability of 21.5% (s.e. = 0.01%) for general
cognitive function. Integration with prior GWAS of cognitive performance and educational attainment yielded several additional
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significant loci. Finally, we found robust polygenic correlations between cognitive performance and educational attainment, several
psychiatric disorders, birth length/weight and smoking behavior, as well as a novel genetic association to the personality trait of
openness. These data provide new insight into the genetics of neurocognitive function with relevance to understanding the
pathophysiology of neuropsychiatric illness.
Molecular Psychiatry (2017) 22, 336–345; doi:10.1038/mp.2016.244; published online 17 January 2017
INTRODUCTION
Genome-wide association studies (GWAS) of complex quantitative
phenotypes such as height1 and body mass index2 have
successfully discovered and replicated hundreds of common
variants meeting criteria for genome-wide significant association.
By contrast, finding genetic loci associated with individual
differences in cognitive ability using GWAS has proven challen-
ging, despite considerable evidence from family and twin studies
indicating that cognitive ability is highly heritable.3 For example,
no genome-wide significant hits were detected in the earliest
multi-cohort GWAS meta-analyses of general cognitive ability in
~ 3500 adults,4 or in ~ 5000 adults,5 or in ~ 18 000 youth.6
However, the first results attaining genome-wide significance, in
three loci on chromosomes 6, 14 and 19, recently emerged in a
GWAS meta-analysis of general cognitive function in 53 949
adults reported by the CHARGE Consortium.7 In addition, a recent
study using data collected as part of the UK Biobank project
reported three genomic regions significantly associated with
performance on a test of verbal numerical reasoning (N= 36 035),
and two independent loci were significantly associated with
performance on a reaction time task (N= 111 483).8 However, in
the same cohort, no genome-wide significant single-nucleotide
polymorphisms (SNP)-based findings were detected for scores on
a memory test, despite the large sample size (N= 112 067),
perhaps due to the low reliability of the very brief assay available.8
Recent GWAS meta-analyses of educational attainment, pro-
posed as a proxy phenotype for cognition,8–12 have demonstrated
that associations can be discovered with sufficient sample size,
with the most recent analysis of 293 723 individuals yielding 74
independent SNPs that reached genome-wide significance.9
Nevertheless, this number of hits is an order of magnitude smaller
than that reported for a similarly powered GWAS meta-analysis of
height, which identified 697 variants that together explained
~ 16% of the variance for adult height in a sample of 253 288
individuals.1 Thus, the complex nature of human cognition,
exacerbated by challenges of precise and reliable measurement,
has rendered it a more difficult phenotype with which to gain
traction in the era of GWAS discovery.
The importance of uncovering the molecular genetic basis of
cognitive functioning is underscored by the fact that neurocog-
nitive deficits represent a critical component of many neuropsy-
chiatric disorders and disease states that can affect health
outcomes across the lifespan. As examples, most early appearing
neurodevelopmental disorders such as autism spectrum
disorder13 and attention-deficit/hyperactivity disorder14 are asso-
ciated with moderate to relatively impairing comorbid deficits in
neurocognitive functioning. Longitudinally, lower cognitive ability
scores in childhood have been linked to decreased rates of
smoking cessation in adulthood.15 The major neuropsychiatric
disorders that typically emerge in early adulthood, such as
schizophrenia,16 bipolar disorder,17 anxiety disorders18 and
depression,19 are also associated with a range of deficits in
neurocognitive function. Human personality traits such as open-
ness to new experiences20 and negative affect21 are, respectively,
associated with better and worse neurocognitive performance.
Individuals with debilitating neurological illnesses such as
Parkinson’s disease22,23 and (by definition) the dementia spectrum
including Alzheimer’s disease24 also suffer from marked neuro-
cognitive impairments. Further, early life cognitive performance
can predict long-term development of illness,25 including
mortality.26 From these findings, it has been suggested that
general cognitive performance may index global bodily integrity,
thereby permitting a potentially broad application of ‘cognitive
epidemiology.’27
Deciphering the genetic overlap between cognition and risk for
neuropsychiatric illness and other health-relevant traits can
provide useful etiological insights and help prioritize likely causal
relationships among complex human traits.28 Methods to estimate
the genome-wide genetic correlation (rg) between two traits using
summary GWAS statistics from published research studies utilizing
linkage disequilibrium (LD) score regression procedures have
recently become available.28,29 LD score regression has been used
recently to show significant genetic correlations between
cognition-related phenotypes and cardiovascular disease,27 phy-
sical health30 and neuropsychiatric illness.31 However, the under-
lying causal variants and the genes through which they act have
yet to be identified.32
There were two major aims of the current study: (1) conduct a
large-scale (n= 35 298) GWAS meta-analysis of general cognitive
function in 24 independent cohorts, to identify SNP-based and
gene-based loci associated with cognition; and (2) determine the
extent of genetic correlation between general cognitive function
and published neurobehavioral phenotypes of interest. These
aims were executed within the context of the Cognitive Genomics
Consortium (COGENT),5,10 an international collaborative effort
designed to study the molecular genetics of cognitive function.
MATERIALS AND METHODS
Participants
To date, COGENT has acquired individual-level neuropsychologi-
cal, demographic, clinical and SNP array data from 24 studies
(comprised of 35 sub-studies) enrolling 35 298 individuals (51.4%
females, mean age of 45.6 (s.d. ± 8.6) years) of European ancestry
drawn from the general population in North America, the United
Kingdom and the European continent. Table 1 provides details of
the individual study cohorts. A few of the cohorts overlap with
those previously reported by the CHARGE consortium,7 so
comparisons to the CHARGE report7 utilize 30 sub-studies
comprising 27 888 fully independent subjects. All subjects
provided written, informed consent to protocols approved by
their institutional ethics boards in accordance with the Helsinki
Declaration.
General cognitive function phenotype
We examined general cognitive function (‘g’), a statistically
derived broadband index of within-person performance on a
neuropsychological test battery. The g phenotype estimates
overall performance and is relatively invariant to the battery used
and specific cognitive abilities assessed.33,34 As in our prior
reports,5,10 for each cohort, g was determined using the first
unrotated component extracted from a principal components
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analysis of individual test scores. Details on phenotypic assess-
ments are provided in the supplement. Briefly, each COGENT sub-
study (n= 35) administered an average of 8 (s.d. ± 4) neuropsy-
chological tests. To be included as a participant in COGENT, data
from at least one neuropsychological measure across at least three
domains of cognitive performance (for example, digit span for
working memory; logical memory for verbal declarative memory;
and digit symbol coding for processing speed), or the use of a
validated g-sensitive measure was required. Digit symbol coding,
digit span, verbal memory for words, visual memory, word
reading, semantic fluency, verbal memory for stories, vocabulary,
phonemic fluency and the trail-making test were the most
common tests administered across cohorts. All individual test
scores were adjusted (using multiple regression) for age2 and sex,
as well as age× sex and age2 × sex interaction terms. The average
internal consistency across test batteries was 71% (s.d. ± 12%), and
the first unrotated principal component accounted for 42% (s.
d. ± 11%) of the variance in overall test performance, which was
expected based on an extensive prior literature (Supplementary
Table S1).35
Genotyping and imputation
All COGENT samples were genotyped on commercial Illumina or
Affymetrix arrays, and a standardized GWAS quality control
pipeline was developed and applied to the genetic data as
described in detail in the Supplementary Information. Participants
were of European ancestry, which was confirmed by analysis of
genotype data using multidimensional scaling. Genetic clustering
in each study was based on multidimensional scaling axis plotting
versus four 1000 Genomes Project super populations (African,
Admixed American, European and Asian), and non-European
participants were removed. Genome-wide imputation was con-
ducted using the largest available cosmopolitan reference
cohort.36
GWAS meta-analysis
In each COGENT sample, allelic association analysis of general
cognitive function was conducted using imputed allele dosages
and the first 10 principal components from the genotyped data to
additionally adjust for population stratification. Cohorts of
unrelated individuals (27 sub-cohorts) were analyzed using
Plink 1.9.37 Samples including related individuals (8 sub-cohorts)
were analyzed with BOLT-LMM38 using a mixed linear model
association function that corrects for population stratification and
relatedness.39 GWAS results were combined for meta-analysis of
all 35 sub-studies using the inverse variance-weighted Z-score
method in METAL.40 SNPs were filtered according to the following
quality control thresholds: (1) minimum imputation quality INFO
score of 0.60; (2) minor allele frequency at least 1%; and (3)
minimum 10 000 samples successfully imputed. Application of
these filters resulted in a total of 8 037 763 high-quality SNPs
available for meta-analysis in up to 35 298 samples. The standard
threshold for genome-wide significance (Po5 × 10− 8) was
applied to SNP results of the GWAS meta-analysis.
Gene-based analysis
Individual SNP results from the meta-analysis were aggregated to
conduct a gene-based analysis using MAGMA.41 SNPs were
mapped to genes based on NCBI build 37.3 and defined by the
start and stop site ± 5 kb, resulting in 18 164 autosomal genes. A
genome-wide significance threshold for gene-based associations
was calculated using the Bonferroni method (α= 0.05/18 164;
P= 2.75 × 10− 6).
Genetic correlation analysis
LD score regression28,29 was used to derive genetic correlations
among GWAS results for general cognitive function and publicly
available GWAS results from multiple neurobehavioral phenotypes
of potential relevance. LD score regression quantifies the extent to
Table 1. Demographic characteristics of the consortium
Cohort Study name Country N Age
mean
Age s.d. Min age Max age N Male % Male
ACPRC Age and Cognitive Performance Research Cohort UK 1461 64.7 6.1 47 85 425 0.29
ADNI Alzheimer's Disease Neuroimaging Initiative USA 259 75.3 5.1 62 90 137 0.53
ASPIS Athens Study of Psychosis Proneness and Incidence
of Schizophrenia
Greece 919 20.7 1.9 18 25 919 1.00
CAMH Center for Addiction and Mental Health Canada 80 48.6 19.4 18 86 38 0.48
CHS Cardiovascular Health Study USA 2931 77.3 5.3 69 96 1208 0.41
CNP UCLA Consortium for Neuropsychiatric Phenomics USA 628 31.1 8.3 21 50 310 0.49
DCC Duke Cognition Cohort USA 1193 27.1 11.6 18 77 558 0.47
DNS Duke Neurogenetics Study USA 455 19.8 1.3 18 22 212 0.47
DUBLIN Galway and Dublin, Ireland Ireland 135 36.2 12.5 18 60 71 0.53
FHS Framingham Heart Study USA 5360 51.7 10.8 25 87 2460 0.46
GCAP NIMH Genes, Cognition and Psychosis Program USA 964 33.8 9.8 18 61 438 0.45
GENADA Genotype–Phenotype Associations in Alzheimer's
Disease
Canada 767 73.4 7.9 48 94 279 0.36
HBCS Helsinki Birth Cohort Study Finland 299 67.7 2.3 64 75 299 1.00
IBG Institute for Behavioral Genetics USA 260 15.9 1.5 12 19 235 0.90
LBC1936 Lothian Birth Cohort 1936 Study UK 951 69.6 0.8 68 71 509 0.54
LLFS Long Life Family Study USA and
Denmark
4081 68.1 14.0 24 90 1861 0.46
LOAD Late Onset Alzheimer's Disease Family Study USA 1033 75.1 5.7 53 95 379 0.37
LOGOS Learning on Genetics of Schizophrenia Spectrum Crete 795 22.5 3.8 18 37 795 1.00
MCTFR Minnesota Center for Twin and Family Research USA 5448 32.5 14.2 17 65 2349 0.43
MUNICH Munich, Germany Germany 1095 47.8 15.3 19 76 540 0.49
NCNG Norwegian Cognitive NeuroGenetics Study Norway 625 47.6 18.3 18 79 214 0.34
PNC Philadelphia Neurodevelopmental Cohort USA 4711 13.8 3.6 8 21 2440 0.52
TOP Thematic Organized Psychosis Research Study Norway 661 31.9 8.9 16 55 359 0.54
ZHH Zucker Hillside Hospital USA 187 35.2 18.8 8 78 108 0.58
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which two phenotypes share genetic etiology (at least with
respect to common variation captured by GWAS). GWAS summary
statistics for 29 phenotypes were downloaded and processed
similar to the pipeline of Bulik-Sullivan et al.29 The following
phenotypes were included—cognition: childhood intelligence,
educational attainment and obtaining a college degree; neurode-
velopmental: autism and attention-deficit/hyperactivity disorder;
neuropsychiatric: schizophrenia, bipolar disorder, anxiety and
major depression; tobacco use: ever smoked cigarettes, number
of cigarettes per day, age of onset of smoking and being a former
smoker; personality: neuroticism, extraversion, openness, agree-
ableness and conscientiousness; brain volume: intracranial
volume, nucleus accumbens, caudate nucleus, putamen, globus
pallidus, hippocampus and thalamus; early childhood growth and
development: infant head circumference, birth length and birth
weight. URLs and references for data sources are provided in the
Supplementary Information.
RESULTS
GWAS of general cognitive function
The QQ plot (Supplementary Figure 1) demonstrates λGC was 1.12,
comparable to the value (1.14) observed in the recent CHARGE
meta-analysis of cognitive ability.7 The LD score regression
intercept of 1.04 indicates that polygenicity, rather than residual
population stratification, accounted for most of the increase in the
mean χ2 statistic.28,29 As shown in the Manhattan plot (Figure 1),
two loci surpassed the genome-wide threshold of P⩽ 5 × 10− 8 in
our GWAS meta-analysis (see Supplementary Table S2 for more
details). On chromosome 2 (Figure 2, top), intronic SNP
rs76114856 in the centromere protein O (CENPO) gene was
genome-wide significant (P= 6.58 × 10− 9). On chromosome 1
(Figure 2, bottom), a cluster of six SNPs located in a lincRNA,
RP4-665J23.1 (also known as LOC105378853), were also genome-
wide significant (top SNP, rs6669072, P= 2.77 × 10− 8). Values of
meta-analytic tests of heterogeneity were low and not statistically
significant, indicating that outlier cohorts did not drive significant
results. In addition, a large 1.4 Mb region at chromosome
17q21.31, coextensive with a known inversion polymorphism,42
harbored 101 nearly significant SNPs (all P’so10− 6; top SNP,
rs916888, P= 8.18 × 10− 8).
Gene-based analysis of general cognitive function
Seven genes in three chromosomal regions (WNT3, PLEKHM1 and
ARHGAP27 at chromosome 17q21.31; TP53 and WRAP53 at
chromosome 17p13.1; and ATXN7L2 and CYB561D1 at chromo-
some 1p13.3) were significantly associated with cognitive function
after Bonferroni correction (Table 2). Several genes at these loci,
including NSF, STH, KANSL1, CRHR1 and MAPT in the 17q21.31
inversion region, demonstrate association just below the
Bonferroni-corrected threshold.
SNP lookups from published GWAS of cognition and educational
attainment
We sought to expand the utility of our data by using it as a lookup
table to confirm and extend associations previously reported in
large-scale GWAS of cognition (from the CHARGE consortium7 and
the UK Biobank8) and educational attainment (from the SSGAC
consortium9). First, we looked up all cognitive SNPs nominally
associated in the CHARGE study at Po10− 5. Importantly, because
of partial sample overlap between COGENT and CHARGE, we re-
ran our cognitive GWAS excluding five overlapping cohorts (CHS,
FHS, HBCS, LBC1936 and NCNG). A meta-analytic P-value was then
generated across the two studies for those loci with nominal
Po0.05 in COGENT. As shown in Supplementary Table S3, we
found support for the three genome-wide significant loci reported
in CHARGE, as well as support for an additional, novel locus at
chromosome 3p22.3 that attained a meta-analytic P-value
surpassing the genome-wide significance threshold (rs1523041,
P= 5.46 × 10− 10). This SNP is intergenic; however, publicly avail-
able gene expression data (from GTEx43) have shown that
rs1523041 is an expression quantitative trait locus for the ARPP21
gene (Supplementary Figure 1).
Next, we examined the genome-wide significant SNPs reported
from the UK Biobank study of verbal numerical reasoning and
reaction time to determine if these were also associated with
general cognitive ability. As shown in Supplementary Table S4, we
found nominally significant support for the chromosome 22 locus
associated with verbal numerical reasoning (top local SNP in
COGENT, rs12170228, P= 0.0053, same direction of effect in
COGENT and UK Biobank). We also showed a similar trend for
the chromosome 7 locus associated with verbal numerical
reasoning (rs9771228, P= 0.074 in COGENT, same direction of
effect in COGENT and UK Biobank). The lone SNP on chromosome
14 that attained genome-wide significance in the UK Biobank
GWAS of verbal numerical reasoning was a rare variant (MAF=
0.1%) that was not available in COGENT and has no known
proxies. For the two loci reported to be associated with reaction
time in UK Biobank, COGENT results demonstrated the same
direction of allelic effects, but were not statistically significant
(COGENT P’s40.6).
Finally, we looked up all SNPs that represented independent,
genome-wide significant hits for educational attainment from the
combined SSGAC+UK Biobank cohorts. Of a total of 164 SNPs
meeting this criteria (as listed in Table 1.16 of that report9), 143
SNPs were directly available in COGENT, and an additional 12 SNPs
were tested by proxy (9 SNPs were unavailable in COGENT even by
proxy). There were 31 educational attainment SNPs that were
nominally significant at Po0.05 in COGENT, all in the same
direction of effect as for educational attainment, representing a
highly significant enrichment (P= 3.9 × 10− 11, binomial test) of
overlap between years of education and cognitive function
(Supplementary Table S5). Further, two SNPs (rs7593947 and
rs2568955) were Bonferroni-corrected significant (for 155 tests;
Po3.23 × 10− 4), suggesting two specific loci for cognition were
discovered using this ‘proxy-phenotype’ method.11 Notably, GTEx
data reveal that rs2568955 is a strongly significant expression
quantitative trait locus (Supplementary Figure 2) in brain tissue for
RPL31P12, although this gene is annotated as a pseudogene;
rs7593947 is an intronic variant in the BCL11A gene.
Genetic correlation of general cognitive function with related
complex traits
SNP heritability (due to common variation) as calculated using LD
score regression was 21.5% (s.e. = 0.01%). This value for h2g is
slightly lower than prior studies7,8 which utilized the GCTA
Figure 1. Manhattan plot depicting results of genome-wide
association study meta-analysis for general cognitive function.
Green arrows indicate loci attaining genome-wide significance
(red line, Po5 × 10− 8). Gray arrow indicates locus at chromosome
17q21.31 approaching genome-wide significance.
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approach in single samples; this attenuation is expected based on
the fact that LD score regression utilizes summary scores as
opposed to full SNP data. The results of the LD score regression-
based genetic correlations with other neurobehavioral pheno-
types are detailed in Table 3. Note that our use of the LD score
regression approach applied a stringent correction (unconstrained
intercept) for potential sample overlap and population stratifica-
tion, as well as a conservative Bonferroni correction for multiple
phenotypes. Not surprisingly, strongly significant positive correla-
tions were observed with the most closely related phenotypes:
years of education (P= 1.48 × 10− 63), obtaining a college degree
(P= 1.88 × 10− 23) and childhood intelligence (P= 1.24 × 10− 13). A
significant negative correlation was observed with schizophrenia
(P= 4.09 × 10− 4), such that genetic load for lower cognitive scores
was associated with greater risk for schizophrenia, consistent with
prior reports from COGENT5 and others.28,30 Similar trends were
observed for attention-deficit/hyperactivity disorder and anxiety,
with nominal (but not Bonferroni-corrected) levels of statistical
significance. A Bonferroni-corrected significant positive correlation
was observed for autism (P= 6.00 × 10− 4), again consistent with
prior reports.30,44
A novel observation is a significant, positive genetic correlation
between general cognitive ability and the personality trait of
openness (rg = 0.48; P= 3.25 × 10
− 4); no other correlations with
personality traits were even nominally significant. (It should be
noted that agreeableness was the only trait for which the
Figure 2. Region plots depicting genome-wide significant loci on Chromosome 2 (top) and Chromosome 1 (bottom). Local linkage
disequilibrium (r2) is color-coded as shown in the legend, and local recombination rate is depicted by the bright blue peaks (magnitude
indicated by the right-hand y axis).
GWAS of general cognitive function
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Table 2. Results of gene analysis (top 20 genes)
Symbol Gene name Chr Start Stop SNPs Parameters N Z stat P-value
WNT3 Wingless-type MMTV integration site family,
member 3
17q21.31 44836686 44901082 127 46 29 063 5.4753 2.18E−08
PLEKHM1 Pleckstrin homology and RUN domain-
containing M1
17q21.31 43508266 43573146 123 23 27 885 4.9724 3.31E−07
TP53 Tumor protein p53 17p13.1 7566720 7595863 94 32 31 813 4.9082 4.60E−07
ARHGAP27 Rho GTPase-activating protein 27 17q21.31 43466268 43515282 128 17 25 183 4.8923 4.98E−07
CYB561D1 Cytochrome b561 family, member D1 1p13.3 110031658 110048063 27 12 31 670 4.7687 9.27E−07
WRAP53 WD repeat containing, antisense to TP53 17p13.1 7584389 7611820 63 20 32 133 4.6221 1.90E−06
ATXN7L2 Ataxin 7-like 2 1p13.3 110021561 110040426 29 11 33 153 4.5842 2.28E−06
PSMA5 Proteasome subunit alpha 5 1p13.3 109936653 109974108 62 23 32 881 4.4835 3.67E−06
NSF N-ethylmaleimide sensitive factor 17q21.31 44663035 44839830 89 20 29 574 4.4412 4.47E−06
SORT1 Sortilin 1 1p13.3 109847187 109945563 147 36 33 175 4.4403 4.49E−06
SYPL2 Synaptophysin-like 2 1p13.3 110004100 110029764 66 16 34 387 4.4171 5.00E−06
CFAP99 Cilia- and flagella-associated protein 99 4p16.3 2415701 2469690 171 43 33 195 4.3569 6.60E−06
KANSL1 KAT8 regulatory NSL complex subunit 1 17q21.31 44102282 44307740 775 22 27 788 4.3536 6.70E−06
STH Saitohin 17q21.31 44071616 44082060 56 12 26 909 4.3028 8.43E−06
SPPL2C Signal peptide peptidase-like 2C 17q21.31 43917256 43929438 69 8 30 906 4.2974 8.64E−06
SP140L SP140 nuclear body protein like 2q37.1 231186894 231273445 365 51 34 250 4.1532 1.64E−05
LRRC37A Leucine-rich repeat containing 37A 17q21.31 44367497 44420160 5 3 26 694 4.1414 1.73E−05
MAPT Microtubule-associated protein tau 17q21.31 43966748 44110700 725 33 29 040 4.079 2.26E−05
CRHR1 Corticotropin-releasing hormone receptor 1 17q21.31 43692710 43918194 1024 75 30 191 3.7486 8.89E−05
PCDH15 Protocadherin-related 15 10q21.1 55557531 56566051 4082 531 33 480 3.218 6.46E−04
Abbreviation: SNP, single-nucleotide polymorphism. Genes that are in bold font were significant after genome-wide Bonferroni correction.
Table 3. Results of genetic correlation using LD score regression
Genetic correlation with other traits using LD score regression
Group Phenotype rg s.e. z P-value
Cognition Childhood IQ 0.89 0.12 7.41 1.24E− 13
College degree 0.66 0.07 9.98 1.88E− 23
Years of education 0.73 0.04 16.83 1.48E− 63
Neuropsychiatric ADHD −0.35 0.16 −2.14 3.22E−02
Alzheimer's − 0.13 0.11 − 1.17 2.41E− 01
Anorexia − 0.02 0.10 − 0.24 8.08E− 01
Anxiety −0.50 0.19 −2.57 1.03E−02
Autism 0.28 0.08 3.43 6.00E− 04
Bipolar 0.00 0.08 − 0.06 9.52E− 01
Major depression 0.10 0.10 0.96 3.35E− 01
Schizophrenia − 0.17 0.05 − 3.53 4.09E− 04
Personality Extraversion − 0.13 0.10 − 1.36 1.74E− 01
Agreeableness 1.24 1.24 1.00 3.17E− 01
Conscietousness 0.10 0.14 0.74 4.61E− 01
Openness 0.48 0.13 3.59 3.25E− 04
Neuroticism − 0.18 0.12 − 1.49 1.35E− 01
Smoking Age of onset 0.21 0.13 1.67 9.49E− 02
Cigarettes per day 0.03 0.11 0.27 7.85E− 01
Ever smoker −0.24 0.08 −3.07 2.13E−03
Former smoker 0.29 0.10 2.80 5.09E−03
Brain volume Accumbens 0.26 0.15 1.74 8.18E− 02
Caudate 0.08 0.10 0.79 4.30E− 01
Hippocampus 0.24 0.13 1.88 6.06E− 02
Intracranial volume 0.14 0.13 1.09 2.77E− 01
Pallidum 0.16 0.13 1.28 2.02E− 01
Putamen 0.13 0.09 1.44 1.50E− 01
Thalamus 0.13 0.12 1.07 2.83E− 01
Early growth Birth length 0.20 0.09 2.13 3.33E−02
Birth weight 0.15 0.05 2.89 3.90E−03
Infant head Circumference 0.19 0.11 1.69 9.04E− 02
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; IQ, intelligence quotient; LD, linkage disequilibrium. Traits that are in bold font were nominally
significant (Po0.05); traits that are italicized were significant after Bonferroni correction.
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SNP-based heritability did not significantly differ from zero
(h2g = 0.016; s.e. = 0.029) and was, therefore, not included in corre-
lational analyses). Higher cognitive ability was strongly genetically
correlated with reduced rates of smoking (P= 2.13 × 10− 4) and
greater rates of quitting smoking (P= 5.09 × 10− 3).
Nominally significant positive genetic correlations were
observed with birth length and weight, with similar trends for
infant head circumference. All genetic correlations with neuroa-
natomic measures trended in the positive direction (larger brain
volumes associated with higher cognitive ability), consistent with
a large literature revealing correlations at the phenotypic level,45
although none of the genetic correlations attained nominal
significance under our conservative approach.
DISCUSSION
Our GWAS meta-analysis of general cognitive function in a sample
of 35 298 individuals of European ancestry revealed two novel
associated SNP loci, three novel gene-based loci, and provided
added support for several previously reported associations.
Strengths of our study included access to individual-level genetic
and neuropsychological data, which allowed us to run each
sample through uniform genotype and phenotype quality control
pipelines. Specifically, the general cognitive function phenotype
was well characterized as a composite score derived from
relatively large batteries of both verbal and nonverbal neuropsy-
chological tests. Genotype data were processed with the latest
imputation platforms and analytic procedures.
Our top GWAS hit was rs76114856, of which the minor T allele
was associated with reduced cognitive performance. This SNP is
an intronic variant in the CENPO gene, which encodes a
component of the interphase centromere complex.46 This gene
is highly expressed in the basal ganglia and thalamus of the
human brain.65 CENPO is located at chromosome 2p23.3 and has
prior GWAS associations to height.1,47 The CENPO gene also had a
nominal association to cognition in our gene-based analysis at
Po0.05, as did neighboring genes NCOA1, PTRHD1 and ADCY3.
The second strongest GWAS signal fell within a large intergenic
non-coding RNA (lincRNA) of unknown function, RP4-665J23.1.
Neighboring protein-coding genes are poorly annotated and do
not provide strong clues as to the potential biological mechanism
underlying the association.
We also found evidence that the chromosome 17q21.31
inversion region is associated with cognitive function. The
chromosome 17q21.31 inversion consists of two haplotypes
(H1 and H2), and the absence of recombination across the
~ 1.5 Mb region between the inverted (H2) and the noninverted
(H1) chromosomes has resulted in two families of chromosomes.48
H1 chromosomes comprise the common (~80% frequency in
European samples) noninverted gene order, whereas the H2
haplotype comprises the inverted gene order (~20% in European
samples).48 There are several sources of evidence that variation at
this locus is associated with neurobehavioral phenotypes. For
example, the 17q21.31 microdeletion syndrome is associated with
the H2 haplotype, which carries additional low-copy repeats
susceptible to non-allelic homologous recombination. The syn-
drome is characterized clinically by developmental delay/intellec-
tual disability, neonatal/childhood hypotonia, friendly behavior
and specific facial dysmorphisms.49 Notably, KANSL1 gene
disruption is associated with the full clinical spectrum of
17q21.31 microdeletion syndrome.49 In addition, the region
harbors the MAPT gene, encoding microtubule-associated protein
tau, a hallmark of multiple dementias.48,50–52 The H1 family of
haplotypes has been associated with increased risk for late-life
tauopathies, diseases marked by the accumulation of MAPT
neurofibrillary tangles in nerve cells, such as sporadic frontotem-
poral dementia,53 Alzheimer’s disease,54 Parkinson’s disease55 and
progressive supranuclear palsy.48 By contrast, the H2 haplotype
has been associated with developmental delay and learning
difficulties,51,56–58 as well as reduced intracranial volume.52
Consistent with these latter observations, our data suggest alleles
corresponding to the H2 haplotype are associated with worse
cognitive performance.
In addition to the loci attaining clear genome-wide significance
through our primary SNP-based and gene-based analyses, our
results confirmed and extended prior GWAS studies of cognitive
and educational phenotypes. Although a prior COGENT report
provided converging evidence for a role of a chromosome 6 locus
(rs1906252),10 we now provide further support for the NPAS3/
AKAP6 locus on chromosome 14 previously reported by the
CHARGE consortium. NPAS3 is a promising candidate gene, as it
has a role in neurodevelopment, and disruptions of this gene have
been associated with psychiatric and intellectual disability
phenotypes.59,60
In the context of prior associations to cognitive and educational
phenotypes, our data identified several loci with strong empirical
support for a role in cognition. Of these, two are noteworthy for
representing known expression quantitative trait locus, permitting
inference of potential biological mechanisms underlying the
statistical associations. Specifically, we found that the major (C)
allele at rs1523041 was strongly (P= 5.46 × 10− 10) associated with
better cognitive performance; this allele drives lower expression of
the ARPP21 gene (Supplementary Figure S1). ARPP21 encodes a
cAMP-regulated phosphoprotein, enriched in the basal ganglia
and cerebellum, that has a central role in the integration of
neurotransmitter inputs into striatal medium spiny neurons.61
Intriguingly, a deletion encompassing this gene segregated with
syndromic intellectual disability in a multiply affected pedigree.62
Similarly, we found that the minor (T) allele of rs2568955 was
associated with poorer cognitive performance, and this allele is
associated with greater expression of RPL31P12 (Supplementary
Figure S2). It should be noted that the strongest expression
quantitative trait locus associations for these SNPs were observed
in non-brain tissue in the GTEx database, perhaps due to smaller
sample sizes available for neuronal phenotypes; these results
should be tested in larger studies of brain expression that will
soon be forthcoming. BCL11A is also a promising candidate gene
for cognition. Haploinsufficiency of this gene has been associated
with intellectual disability in a large clinical study, with the
phenotype recapitulated in Bcl11a knockout mice, which was
shown to be mediated through downstream transcriptional
dysregulation in the hippocampus and cortex.63
Analysis of the genetic correlation between general cognitive
function and various other phenotypes revealed that better
cognitive performance was robustly genetically correlated with
more years of schooling, decreased likelihood of smoking and
decreased risk for several psychiatric disorders (as well as
increased risk for autism). These results are generally consistent
with recent genetic correlation studies of cognitive phenotypes30
and proxy phenotypes for cognition.9 The personality trait of
openness, a core component of the ‘Big 5’ model of personality,
was positively correlated with cognitive ability at the genetic level.
This novel finding is consistent with a prior literature in which
moderate phenotypic correlations (values for r ranging between
0.25 and 0.5) between openness and cognitive ability have been
repeatedly observed,20,64 whereas cognition is generally uncorre-
lated with other personality dimensions. Moreover, phenotypic
data from twin and family studies have suggested a specific
genetic correlation between openness and general cognitive
ability.65 Longitudinal studies have suggested a model in which
openness may serve as a ‘buffer’ against cognitive decline, as has
been proposed in the Openness-Fluid-Crystallized-Intelligence
model applied to late adulthood.66 Positive genetic correlations
with birth length and weight suggest a critical role for prenatal
developmental factors in the subsequent manifestation of
cognitive ability throughout the lifespan.
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One limitation of the current study is the wide age range of
subjects, both across cohorts and within cohorts. Although we
sought to control for confounding effects of age using covariates,
genetic influence on cognitive ability is somewhat reduced in
early childhood and adolescence relative to adulthood.67 In
addition, late-life effects of cognitive decline may be mediated
through somewhat disparate molecular pathways; this may
explain the relatively weak effect of variation at APOE compared
with prior GWAS meta-analysis.7 Nevertheless, cognitive abilities
are remarkably stable across the entire lifespan,68 so we chose to
include all available samples in order to maximize sample size
and power.
Similarly, we chose to include cohorts with widely disparate
neurocognitive batteries, which undoubtedly contributed to noise
surrounding the estimates of g. Moreover, as demonstrated in
Supplementary Table 1, the degree to which the first principal
component captured the shared variance across tests was
heterogeneous across cohorts. In general, cohorts with fewer
available tests demonstrated greater loading onto the first factor,
but with less reliability as determined by Cronbach’s α. However,
in each case, the scree plots clearly demonstrated a steep drop in
variance accounted for beyond the first component, consistent
with the known properties of g. Moreover, in a subset of subjects
in one of the cohorts (TOP), we previously5 compared our
computed g with estimated intelligence quotient from a
4-subscale composite from the WASI,69 and observed a strong
correlation (r= 0.67, Po10− 46). Thus, we are confident that our
computed index for each cohort was primarily reflecting general
cognitive ability, but it is equally certain that substantial
heterogeneity existed across cohorts, thereby reducing power in
comparison with more easily measured quantitative traits such as
height. Notably, it has been empirically demonstrated that such
noise is more than compensated by increases in statistical
power.70 Given the expense in conducting comprehensive
cognitive assessments, we chose to include all available cohorts
meeting our basic criteria.
Despite the statistical significance of the novel GWAS loci
identified in the current report, it is important to emphasize that
the effect sizes for individual SNPs are very small; each of our top
two SNPs individually account for ~ 0.1% of the variance in
cognitive performance. For context, these effect sizes are
considerably smaller than those observed for the top individual
loci associated with other quantitative anthropometric traits such
as height and weight,1,2 This difference may reflect the complexity
of the underlying genetic architecture of cognition, as480% of all
genes are expressed in brain;71 this complexity has also slowed
progress in identifying genetic loci for neuropsychiatric disorders,
given the potentially large mutational target.70 This challenge is
exacerbated by the fact that general cognitive ability is a latent
trait that is only indirectly captured by the available phenotypic
measures, which are also quite heterogeneous across cohorts.
Moreover, the well-known winners’ curse phenomenon72 will
likely result in even further reduction of our effect size estimates in
future studies of independent cohorts. However, as described in
the preceding paragraphs, results of the present study can provide
important information about the molecular underpinnings of
cognitive function as well as clues relevant to the etiology
neuropsychiatric disorders and other conditions relevant to
human health. Although it is striking that general cognitive ability
remains the quantitative trait most challenging to GWAS
methodology, the recent success of very large-scale GWAS in
educational attainment9 provides optimism that cognition is now
at the beginning of the slope of increasing GWAS discovery that
has been observed for all heritable complex traits.73
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